autoimmune

Infliximab is a monoclonal antibody, a human-mouse chimeric monoclonal antibody that inhibits TNF-α and prevents TNF-α from interacting with TNFR1 and TNFR2. Infliximab can be used to treat Crohn's disease and rheumatoid arthritis.

Rituximab is an anti-CD20 chimeric monoclonal antibody used to study certain autoimmune diseases and cancers.

Rozanolixizumab (RYSTIGGO) is a high-affinity humanized immunoglobulin G4 monoclonal antibody targeting Fc receptors (FcRn) in human newborns for the study of pathogenic IgG in autoimmune and alloimmune diseases.

PD-1 PD-L1-IN-20 is a small molecule inhibitor of PD-1 PD-L1 protein-protein interaction, blocking the interaction with an IC50 of 5.29 nM. PD-1 PD-L1-IN-20 can be used to study cancer, infectious diseases, and autoimmune diseases.

Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody that inhibits human and chorioallantoic monkey IL-1β with IC50 values of 43.6 and 40.8 pM, respectively. It exhibits anti-inflammatory activity by neutralizing IL-1β signaling, and it has been used for the treatment of gout and coronary artery disease.

Inebilizumab is a humanized anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used to treat a range of autoimmune diseases associated with CD19 B cells, such as multiple sclerosis and optic neuromyelitis.

Otelixizumab (ChAglyCD3) is a chimeric monoclonal antibody targeting CD3, used in research on Type 1 diabetes and autoimmune diseases.

Tabalumab (LY2127399), a humanized monoclonal antibody (IgG4 type) targeting B-cell activating factor (BAFF), exhibits neutralizing activity against both membrane-bound and soluble BAFF. This compound is relevant for research into autoimmune diseases, including rheumatoid arthritis, renal failure, and systemic lupus erythematosus [1].

Epratuzumab (AMG 41) is a humanized monoclonal antibody targeting CD22, also a tumor imaging agent that induces CD22 phosphorylation. It is used in autoimmune disease research.

Perakizumab (RG4934) is a humanized monoclonal antibody targeting IL-17A, used in the study of psoriatic arthritis and other autoimmune diseases.

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a human IgGκ monoclonal antibody that specifically targets and inhibits IL-17A's receptor interaction, making it useful for researching autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis [1].

Vobarilizumab (ALX-0061) is a humanized, specific monoclonal antibody targeting IL-6R and albumin (ALB), consisting of an anti-IL-6R domain and an anti-human albumin domain, used in the study of rheumatoid arthritis and other autoimmune diseases.

Certolizumab pegol (Certolizumab) is a polyethylene glycolated and humanized anti-TNF-α monoclonal antibody for the study of autoimmune diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).

Tibulizumab (LY 3090106), a tetravalent bispecific monoclonal antibody, selectively binds to B-cell activating factor (BAFF) and IL-17A with dissociation constants (Kd) of 60 pM and 14 pM, respectively. This specificity renders it a valuable tool for autoimmune disease research.

Lulizumab pegol (BMS-931699) is an anti-CD28 antibody antagonist that inhibits T-cell proliferation, offering potential therapeutic applications for kidney transplantation and autoimmune disease research [1].

Melredableukin alfa (RO-7049665) is a fusion protein consisting of a human IgG1-κ and a mutated human interleukin 2 (IL2 mutein), connected by a peptide linker, and is being researched for potential applications in autoimmune hepatitis and ulcerative colitis [1].

Orticumab (MLDL1278A) is an antibody that targets and inhibits oxidized or malondialdehyde-modified low-density lipoprotein (oxLDL), modulating autoimmune responses against oxLDL and showing potential to improve atherosclerosis in animal models. Additionally, Orticumab has been researched for its effectiveness in improving psoriasis [1] [2].

K1-70 is a humanized antibody targeting TSHR, used in the study of autoimmune diseases and endocrine disorders.

Dapirolizumab is an anti-CD40 monoclonal antibody used in research on systemic lupus erythematosus (SLE) and other autoimmune diseases.

Temtokibart is a humanized monoclonal antibody targeting IL22RA1, used in autoimmune and inflammatory disease research.

Batoclimab, a human anti-FcRn monoclonal antibody, is utilized in the study of IgG-mediated autoimmune diseases [1].

Tregalizumab, a humanized IgG1-type monoclonal antibody targeting CD4, selectively activates regulatory T cells (Tregs) with suppressive functions in vitro and has potential applications in researching autoimmune diseases (due to inadequate Treg activity) and allergies [1] [2] [3].

Telitacicept (RC18), a fully human TACI-Fc fusion protein, acts as a dual inhibitor of B lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), effectively impeding B lymphocyte proliferation. This compound is applicable in researching B-cell autoimmune diseases [1].

Human IgG4 (S228P) kappa, Isotype Control is a human-mouse chimeric antibody that can be used to study autoimmune diseases.